Severe Hypertriglyceridemia Clinical Trials

33 clinical trials for Severe Hypertriglyceridemia across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias — RECRUITING · PHASE1
• Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis — RECRUITING · PHASE3
• A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia — RECRUITING · PHASE2
• A Study to Assess the Safety, Tolerability and Efficacy of ION775 — RECRUITING · PHASE2
• A study to assess the effectiveness and safety of EPANOVA™ in patients who have severe hypertriglyceridemia, when compared to treatment with olive oil over 12 weeks — COMPLETED · PHASE3
• Study of Plozasiran in Adults With Severe Hypertriglyceridemia — ACTIVE_NOT_RECRUITING · PHASE3
• Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia — ACTIVE_NOT_RECRUITING · PHASE3
• Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study) — TERMINATED · PHASE3
• A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia — NOT_YET_RECRUITING · PHASE3
• To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia — COMPLETED · PHASE3
• A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia — NOT_YET_RECRUITING · PHASE3
• CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia — NOT_YET_RECRUITING · PHASE1
• Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) — TERMINATED · PHASE3
• Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study) — TERMINATED · PHASE3
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia — COMPLETED · PHASE2
• Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia — COMPLETED · PHASE2
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia — COMPLETED · PHASE3
• A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia — COMPLETED · PHASE2
• CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) — ACTIVE_NOT_RECRUITING · PHASE3
• Compassionate Use of Evinacumab — OTHER
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia — COMPLETED · PHASE3
• ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia. — TERMINATED · PHASE3
• Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia — COMPLETED · PHASE2
• Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis — COMPLETED · PHASE2
• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function — COMPLETED · PHASE3
• Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment — COMPLETED · PHASE3
• Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL — WITHDRAWN · PHASE3
• A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia — COMPLETED · PHASE2
• The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL) — WITHDRAWN · PHASE3
• Epanova® for Lowering Very High Triglycerides — COMPLETED · PHASE2
• An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis — COMPLETED · PHASE1
• Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation — COMPLETED · PHASE2
• Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia — OTHER · PHASE3

Refine this search